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Role of genetic variants of the renin-angiotensin system in chronic
renal allograft injury. In the vast majority of patients undergoing kidney
transplantation, long-term success is markedly limited by a gradual
decrease in graft function over time, often termed as “chronic rejection”
or “chronic allograft injury.” Although there have been no formal studies
examining the role of genetic factors other than those related to histo-
compatibility for the development or progression of chronic allograft
rejection, it is likely that genetic factors affecting blood pressure regula-
tion, mesangial or vascular proliferation, or aspects of inflammatory
response including thrombosis, chemotaxis, or fibrosis may play an
important role in this complex syndrome. There is currently little hope
that the responsible genes can be identified through sib-pair or linkage
studies in families. Therefore, the study of candidate genes selected on the
basis of our current understanding of the pathophysiological mechanisms
involved in the chronic rejection response appears the only feasible
approach. Thus far, studies have focused mainly on the role of functional
genetic variants of the renin-angiotensin system on renal allograft funding.
These studies, however, have not identified these variants as important
determinants of renal allograft survival. Clearly, future studies will have to
address the role of other variants of this system as well as genes encoding
for other systems deemed to be of pathophysiological significance for the
development and progression of chronic transplant injury.
During the last two decades, remarkable improvements in
immunosuppression have resulted in dramatic improvements in
short-term renal allograft survival. However, in the vast majority
of patients undergoing kidney transplantation, long-term success
is markedly limited by a gradual decrease in graft function over
time. The mechanisms leading to the progressive loss of graft
function, often termed “chronic rejection” or “chronic allograft
injury,” remain largely unknown and no effective therapy is
available [1].
Thus far, both immunologic and non-immunologic factors have
been implicated in the development and progression of chronic
allograft injury. While the degree of HLA mismatch has not been
unequivocally found to be an important determinant of chronic
rejection [2, 3], the most consistent immunologic factor related to
chronic allograft injury has been the occurrence of acute rejection
episodes [3, 4]. Nevertheless, although the introduction of more
potent immunosuppressive drugs including cyclosporine has re-
sulted in a marked reduction in acute allograft rejection, to date
this has not had a discernible effect on long-term allograft survival
[1, 3].
Non-immunological factors implicated in chronic allograft in-
jury include ischemia time, extremes of age of donor, smoking
history, and the presence of hypertension, hyperlipidemia or
proteinuria [1]. Despite these associations found in epidemiolog-
ical cohort and cross-sectional studies, the protective value of
intervention with specific anti-hypertensive, lipid-lowering, or
anti-proteinuric drugs in preventing chronic allograft rejection has
yet to be demonstrated.
Although there have been no formal studies examining the role
of genetic factors other than those related to histocompatibility
for the development or progression of chronic allograft rejection,
it is likely that genetic factors play an important role in this
complex syndrome [1]. Biopsy findings characteristically show
vascular sclerosis with mural thickening and occlusion of renal
arteries and ischemic glomeruli, interstitial infiltration by macro-
phages and lymphocytes, and interstitial fibrosis [5]. It is thus
conceivable that genetic factors affecting blood pressure regula-
tion, mesangial or vascular proliferation, or aspects of inflamma-
tory response including thrombosis, chemotaxis, or fibrosis may
determine the extent and progression of chronic allograft injury.
These genetic factors can be active both in the host or within the
transplanted kidney.
Given the complexity of the factors apparently involved in
chronic rejection, there is no reason to believe that a single gene
or genetic variant will act as a strong determinant of the loss of
renal function by itself. It is more likely that a variety of genetic
factors will play a role in determining the response to environ-
mental factors, development of risk factors like hypertension,
dyslipidemia or proteinuria, development of allograft injury, and
the rate of progression (Fig. 1). As a result, a host of candidate
genes could be envisioned to play a role at one or more of these
steps in the development of chronic rejection. Luckily, develop-
ment of end-stage renal failure remains a relatively rare event,
and therefore studies in families with several members undergo-
ing kidney transplantation are largely limited to anecdotal reports
in families with hereditary renal disease. While in some instances
genotyping non-affected parents may play a role in demostrating
preferential transmission of deleterious alleles to affected off-
spring, there is currently little hope that genes determining the
processes involved in chronic allograft injury can be identified
through affected sibling-pair or linkage studies in families. There-
fore, the study of candidate genes selected on the basis of our
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current understanding of the pathophysiological mechanisms in-
volved in the chronic rejection response appears to be the only
feasible approach. It is obvious that the study of functional
variants of genes implicated in the development of hypertension
or inflammatory response should serve as prime candidates for a
role in chronic rejection.
ROLE OF THE RENIN-ANGIOTENSIN SYSTEM
Based on this line of reasoning, the components of the renin-
angiotensin system are clearly candidate genes of considerable
interest. Several lines of evidence do indeed suggest a role for this
system in the development and progression of chronic allograft
injury. Thus, hypertrophy of the juxtaglomerular apparatus is a
common histological feature of chronic rejection and presumably
indicates increased renin secretion [6]. Higher plasma renin
activity has been reported in patients with worsening of graft
function [7], and has also been implicated as a cause of post-
transplant hypertension [8], an important risk factor for allograft
injury [1]. The importance of the renin-angiotensin system for
immune-mediated injury in renal [9], cardiac [10], and aortic [11]
allografts in rats has been previously demonstrated by attenuation
of injury by administration of angiotensin converting enzyme
(ACE) inhibitors. Also, short-term studies in humans have dem-
onstrated reduced proteinuria with ACE inhibition in hyperten-
sives with renal transplants [12].
Recent studies have identified a variety of genetic variants of
the components of the renin-angiotensin system [13, 14]. This
article focuses on the findings derived from studies of these
variants in patients with renal allograft transplantation.
ANGIOTENSINOGEN GENE
Angiotensinogen (AGT) or renin-substrate, a protein synthe-
sized primarily in the liver but also in other tissues including the
kidney, is catalyzed by renin to angiotensin I, which is subse-
quently converted to angiotensin II by the angiotensin-converting
enzyme. Several family and sibling-pair studies have demon-
strated a linkage between the angiotensinogen-gene (AGT) locus
and essential hypertension [13, 15, 16]. Furthermore, a biallelic
variant encoding either for a methionine (M) or threonine (T) at
codon 235 of the mature angiotensinogen protein, associated with
increased circulating angiotensinogen levels [13], has been linked
to an increased risk for the development of hypertension both in
Caucasian [13, 17, 18] and Japanese [19–21] humans. We have
also reported that the AGT 235M/T-variant is associated with an
early onset of hypertension in German Caucasian populations
both in Berlin and Heidelberg [22]. In a recent meta-analysis we
found a 20 to 40% increase in the risk for hypertension associated
with the AGT 235T variant in Caucasians [23]. This variant of the
angiotensinogen gene is now known to be in almost complete
linkage disequilibrium with a biallelic variant involving the sub-
stitution of an adenine (A) for a guanine (G) nucleotide at
position 26 upstream from the initiation site of transcription [24].
This 26A variant apparently binds transcription factors affecting
the basal rate of transcription, thereby possibly accounting for the
association between the AGT 235T variant and increased plasma
levels of angiotensinogen.
Given that hypertension is an important risk factor for the
progression of chronic allograft injury, and as many as 70% of all
renal transplant recipients develop hypertension [1], it is conceiv-
able that a variant of the angiotensinogen gene associated with
essential hypertension may also increase the risk for the develop-
ment of post-transplant hypertension. In rats exogenous angio-
tensinogen increases blood pressure under a low salt diet, dem-
onstrating that with high renin levels, availability of
angiotensinogen determines angiotensin I generation [25]. As
higher levels of renin activity are found in a large proportion of
renal-allograft recipients [7, 26, 27], one may expect that individ-
uals harboring the AGT 235T variant would be more prone to
developing post-transplant hypertension.
We recently addressed this question in a study on 269 consec-
utive patients undergoing kidney transplantation between 1988
and 1993 at our hospital [28]. Genomic DNA for genetic analysis
was prospectively collected from all recipients and donors and the
Fig. 1. Relationship between genetic factors and determinants of chronic
renal allograft injury.
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presence of hypertension, and graft survival was analyzed by
blinded review of all case records over a follow-up period up to 30
months. Angiotensinogen genotype was determined by a muta-
genically-separated allele-specific polymerase-chain-reaction
technique. While post-transplant hypertension was present in
78% of all patients, we found no relationship between either
donor or recipient genotype and the presence or severity of
post-transplant hypertension. Furthermore, there was no relation-
ship between angiotensinogen genotype and graft survival during
the course of the study. These findings clearly do not support the
hypothesis that the M235T-variant of the angiotensinogen gene is
a risk factor for the development of post-transplant hypertension.
This finding may indicate that other factors including administra-
tion of cyclosporine, salt and fluid retention, or administration of
glucocorticoids may have a greater impact on the development of
hypertension than the angiotensinogen genotype. However, this
study does not rule out that this genetic variant may predispose to
the development of post-transplant hypertension or chronic re-
jection in a subset of patients.
ANGIOTENSIN CONVERTING ENZYME
In most tissues ACE is the key catalyst of the conversion of
angiotensin I to angiotensin II. Serum and tissue levels of ACE
are now known to be under genetic control [14]. Thus, individuals
harboring a deletion (D) of a 289 bp Alu sequence located in
intron 16 of the gene display higher humoral and tissue activity of
this enzyme than individuals who are homozygous for the inser-
tion (I) allele [14, 29]. Although ACE exists in a free circulating
form, most of it is expressed as a transmembrane protein that is
also present both in endothelial and epithelial cells in the kidney
[30].
Apart from its role in the renin-angiotensin system, ACE is also
the major inactivating enzyme of bradykinin, substance P, and
other peptides that play important roles in several aspects of
inflammatory and immunological responses [31]. Importantly,
large amounts of ACE are expressed constitutively in macro-
phages [32], monocytes, and T-lymphocytes [33], and in the latter,
ACE expression is also known to be under genetic control, with
homozygotes for the D-allele expressing markedly higher levels of
this enzyme than other individuals [33].
Recent studies have now implicated the ACE-D variant as a risk
factor for the development of diabetic nephropathy [34–37] and
an increased rate of progression of IgA nephropathy [38–40], but
these findings have not been confirmed by all investigators [23,
41–45]. In 1995 Gaciong et al also reported a higher prevalence of
the ACE-D allele (qD 5 0.63) in kidney transplant recipients
versus healthy age-matched blood donors (qD 5 0.52), and
suggested that this may be due to the fact that the ACE-D allele
is a risk factor for the progression of renal disease [46]. In a more
recent study, homozygosity for the ACE-D variant has also been
described as a risk factor for early development of end-stage renal
failure in patients with PKD1 adult polycystic kidney disease [47].
The implication of this genetic variant in the progression of a
variety of renal diseases of considerable etiological heterogeneity
suggests that the role of this polymorphism may be rather
unspecific, possibly affecting structural or inflammatory processes
common to the majority of progressive renal disorders.
Based on these findings, we recently examined the hypothesis
Fig. 2. Allelic frequencies of the ACE-D allele
in donors and recipients undergoing renal
tranplantation, long-term survivors of renal
transplantation, and healthy controls (Adapted
from [48, 49]).
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that the ACE I/D genotype may be related either to the onset or
progression of chronic allograft injury. This question was ad-
dressed in three distinct settings: a single-center cohort of 269
Caucasian patients undergoing kidney transplantation between
1988 and 1993 in whom we analyzed the appearance of biopsy-
confirmed chronic rejection or allograft loss over a follow-up
period of 30 months [48]; a multi-center case-control study in 328
patients with an allograft survival of less than three years (median
survival 11 months) versus 461 patients with an allograft survival
of at least three years (median survival 65 months) [48]; a group
of 86 transplant recipients with a graft survival of at least 10 years
(median survival 156 months) [49]. Neither in the cohort nor in
the case control was there a significant effect of recipient or donor
ACE genotype on transplant survival. Furthermore, the frequency
of the ACE-D allele both in donors and recipients was similar to
that reported by us and others in healthy Caucasian controls (Fig.
2). Likewise, in the patients surviving with a renal allograft for at
least ten years, the frequency of the ACE-D allele was similar to
that found in patients with early graft loss.
This lack of relationship between the ACE-I/D genotype is also
in line with a recent report on a Dutch cohort [50] of 318 patients
with at least one year of graft survival. In that study, the relative
risk for graft failure over a five year follow-up period in DD
recipients was 1.82 (95% CI 0.66 to 5.01) versus the II genotype.
After correction for acute rejection and inclusion of patients dying
with a functioning allograft, the five-year allograft failure in DD
recipients was higher than in II recipients (RR 1.92; 95% CI 0.91
to 4.02), but this result was not statistically significant. These
authors, therefore, likewise concluded that neither donor nor
recipient ACE-genotype significantly affected graft survival.
Nevertheless, the lack of relationship between renal allograft
survival and the ACE I/D genotype does not completely rule out
a role for increased ACE activity in the development of chronic
allograft rejection. Other variants of the ACE gene [51] might yet
be associated with either the development of end-stage renal
failure or the progression of renal injury including chronic trans-
plant rejection, and the ACE-gene therefore remains an attractive
candidate gene. Furthermore, given that the development of
chronic transplant rejection is probably the result of a complex
interaction between a variety of immunologic, genetic, and envi-
ronmental factors [1], these findings do not completely rule out an
importance of the ACE genotype in certain subsets of patients or
under certain environmental conditions.
Since the ACE-D allele has also been associated with increased
humoral and tissue activity of this enzyme [14, 29, 33], it appears
worthwhile to pursue the question of whether individuals with the
DD genotype profit more from therapeutic blockade of the
renin-angiotensin system than other individuals. This suggestion is
based on the findings of Yoshida et al [39], who demonstrated a
significant reduction of proteinuria following ACE inhibition in
patients with IgA nephropathy and the DD genotype, but not in
patients with the ID or II genotype. Similarly, individuals harbor-
ing the D allele were found to have a larger decrease in blood
pressure during ACE inhibition than II patients [52], indicating
that the ACE genotype may significantly influence the therapeutic
response to blockade of the renin-angiotensin system.
SUMMARY AND OUTLOOK
While the complexity and variability of chronic allograft rejec-
tion makes it very likely that genetic factors play a role in the
development or progression of this syndrome, current studies
focusing on the renin-angiotensin system have thus far not
identified genetic variants of this system as important determi-
nants. These negative findings, however, do not rule out a role for
this system in the functional, inflammatory, or structural changes
found in chronic rejection. Clearly, future studies will have to
address the role of genetic variants of genes coding for compo-
nents of other systems that may play a role in these processes.
However, given our current limited understanding of the patho-
mechanisms involved, the host of potential candidate genes makes
this a daunting, if not impossible, task. Hopefully, further exper-
imental and clinical studies will improve our understanding of the
pathophysiological mechanisms determining progressive renal
allograft injury and will thus facilitate the selection of relevant
candidate genes for future investigations.
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